![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Merck | Home
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Discover Job Opportunities at Merck | Merck Careers
Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.
Company fact sheet - Merck.com
Dec 31, 2023 · Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. View the list of products marketed in the U.S.
Who we are - Merck.com
Merck aspires to be the premier research-intensive biopharmaceutical company in the world. Learn about our commitment to save and improve lives.
Products list - Merck.com
For information about Merck’s products and services including the reporting of an Adverse Event or Product Quality Complaint with a specific Merck product, please call the Merck National Service Center.
What we do - Merck.com
Merck aspires to be the premier research-intensive biopharmaceutical company in the world. Learn about our commitment to save and improve lives.
Merck Announces Third-Quarter 2024 Financial Results
Oct 31, 2024 · Merck now expects its full-year non-GAAP effective income tax rate to be between 16.0% and 17.0%, which includes an unfavorable impact related to the one-time charge associated with the acquisition of CN201 (MK-1045) from Curon.
Vaccines - Merck.com
Merck's work in vaccines focuses on making certain diseases a thing of the past. At Merck, we follow the science.
Investor relations - Merck.com
Jan 31, 2025 · Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business.
Merck to Acquire EyeBio
May 29, 2024 · RAHWAY, N.J. & NEW YORK--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.